# Ticagrelor Administered as Standard Tablet or Orodispersible Formulation

> **NCT03822377** · PHASE3 · COMPLETED · sponsor: **Azienda Ospedaliero Universitaria di Sassari** · enrollment: 130 (actual)

## Conditions studied

- ST Elevation Myocardial Infarction
- NSTEMI - Non-ST Segment Elevation MI

## Interventions

- **DRUG:** Ticagrelor orodispersible tablets
- **DRUG:** Ticagrelor standard tablets

## Key facts

- **NCT ID:** NCT03822377
- **Lead sponsor:** Azienda Ospedaliero Universitaria di Sassari
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-27
- **Primary completion:** 2020-08-31
- **Final completion:** 2020-08-31
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2021-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03822377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03822377, "Ticagrelor Administered as Standard Tablet or Orodispersible Formulation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03822377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*